These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 21129630)

  • 1. Emerging carbapenemases: a global perspective.
    Walsh TR
    Int J Antimicrob Agents; 2010 Nov; 36 Suppl 3():S8-14. PubMed ID: 21129630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging threat of acquired carbapenemases in Gram-negative bacteria.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2010 Feb; 16(2):99-101. PubMed ID: 20085603
    [No Abstract]   [Full Text] [Related]  

  • 3. Carbapenemases: a brief review for pediatric infectious disease specialists.
    Overturf GD
    Pediatr Infect Dis J; 2010 Jan; 29(1):68-70. PubMed ID: 20035208
    [No Abstract]   [Full Text] [Related]  

  • 4. High prevalence of co-expression of newer beta-lactamases (ESBLs, Amp-C-beta-lactamases, and metallo-beta-lactamases) in gram-negative bacilli.
    Chatterjee SS; Karmacharya R; Madhup SK; Gautam V; Das A; Ray P
    Indian J Med Microbiol; 2010; 28(3):267-8. PubMed ID: 20644325
    [No Abstract]   [Full Text] [Related]  

  • 5. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.
    Pfeifer Y; Cullik A; Witte W
    Int J Med Microbiol; 2010 Aug; 300(6):371-9. PubMed ID: 20537585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging NDM carbapenemases.
    Nordmann P; Poirel L; Walsh TR; Livermore DM
    Trends Microbiol; 2011 Dec; 19(12):588-95. PubMed ID: 22078325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired metallo-beta-lactamases: an increasing clinical threat.
    Rossolini GM
    Clin Infect Dis; 2005 Dec; 41(11):1557-8. PubMed ID: 16267726
    [No Abstract]   [Full Text] [Related]  

  • 8. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
    Boyle DP; Zembower TR
    Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of disk preparation on detection of metallo-beta-lactamase-producing isolates by the combined disk assay.
    Andrade SS; Picão RC; Campana EH; Nicoletti AG; Pignatari AC; Gales AC
    J Clin Microbiol; 2007 Jun; 45(6):2058-60. PubMed ID: 17409202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved performance of the modified Hodge test with MacConkey agar for screening carbapenemase-producing Gram-negative bacilli.
    Lee K; Kim CK; Yong D; Jeong SH; Yum JH; Seo YH; Docquier JD; Chong Y
    J Microbiol Methods; 2010 Nov; 83(2):149-52. PubMed ID: 20801167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Beta-lactamases and their role in resistance. PART 2: beta-lactamases in 21st century].
    Bedenić B
    Lijec Vjesn; 2005; 127(1-2):12-21. PubMed ID: 16145868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
    Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
    New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control.
    Carmeli Y; Akova M; Cornaglia G; Daikos GL; Garau J; Harbarth S; Rossolini GM; Souli M; Giamarellou H
    Clin Microbiol Infect; 2010 Feb; 16(2):102-11. PubMed ID: 20085604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of carbapenemases in Gram-negative bacteria in Hamburg, Germany.
    Hentschke M; Goritzka V; Campos CB; Merkel P; Ilchmann C; Lellek H; Scherpe S; Aepfelbacher M; Rohde H
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):312-5. PubMed ID: 21899979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The rise of resistant gram-negative bacteria].
    Kuijper EJ; van Dissel JT
    Ned Tijdschr Geneeskd; 2010; 154(45):A2868. PubMed ID: 21118590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia.
    Peleg AY; Franklin C; Bell JM; Spelman DW
    Clin Infect Dis; 2005 Dec; 41(11):1549-56. PubMed ID: 16267725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically significant carbapenemases: an update.
    Walsh TR
    Curr Opin Infect Dis; 2008 Aug; 21(4):367-71. PubMed ID: 18594288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.